1. Accurso FJ, Sontag MK, Wagener JS (2005) Complications associated with symptomatic diagnosis in infants with cystic fibrosis. J Pediatr 147(3 Suppl):S37–S41
2. Barataud B (1992) Au nom de nos enfants. Edition no. 1, Paris
3. Bennett FC, Guralnick MJ (1991) Effectiveness of development intervention in the first five years of life. Pediatr Clin North Am 38(6):1513–1528
4. Commission Staff Working Document on the experience acquired as a result of the application of Regulation (EC) No 141/2000 on orphan medicinal products and account of the public health benefits obtained. SEC(2006) 832(20.06.06).
http://ec.europa.eu/enterprise/pharmaceuticals/orphanmp/doc/orphan_en_06-2006.pdf
. Cited 28 Sept 2009
5. De Varax A, Lettelier M, Bortlein M (2004) Study on orphan drugs. Phase II: consideration on the application of article 8.2 of EU regulation 141/2000 concerning orphan drugs. Available via ALCIMED.
http://ec.europa.eu/enterprise/pharmaceuticals/orphanmp/doc/pricestudy/final_final_report_part_1_web.pdf
. Cited 28 Sept 2009